Cord blood (CB) transplantation has greatly extended availability of a hematopoietic cell transplant (HCT) to patients who would not otherwise have received this curative treatment. CB has several advantages over bone marrow (BM) and mobilized peripheral blood (mPB), including ease and safety of collection, ready availability, and lessened acute and chronic graft vs. host disease (GVHD). However, a disadvantage with CB is low numbers of nucleated cells, hematopoietic progenitors (HPC), and likely stem cells (HSC), compared with BM or mPB, which has translated into increase risk of graft failure, delayed engraftment, and delayed immune reconstitution. Based on our published laboratory and preclinical animal model studies, preliminary clinical data, and mechanistic studies on CD26/Dipeptidylpeptidase (DPP) IV activities reported herein, we believe that inhibition of CD26/DPPIV will significantly enhance engraftment capability of limiting numbers of human CB cells, and accelerate time to engraftment of single CB units. This multi-PI grant proposes the following specific aims:
Aim 1 : Conduct a multicenter phase II clinical trial to assess efficacy and safety of systemic inhibition of CD26/DPPIV using sitagliptin, to enhance engraftment of single CB units in adults with hematological cancers. Hypothesis: Inhibition of CD26/DPPIV by systemic administration of CD26 inhibitor sitagliptin will enhance engraftment, without negatively impacting relatively lower levels of GVHD associated with single CB transplantation. Primary Objective: Evaluate proportion of patients with neutrophil recovery by day +30 after transplant as a measure of speed of engraftment. Using an optimal two-stage design, <50% of patients engrafting by day +30 will be considered unacceptable (null hypothesis;H0: p0<0.5), while 70% or more engrafting will be considered worthy of further study (alternate hypothesis: H1: p1e0.7).
Sub aims are: a) Evaluate time to platelet engraftment, patient survival, graft failure, relapse rate, acute and chronic GVHD levels;b) Use correlative assays to assess recovery of immune cells through phenotypic and functional analysis;and c) Assess blood levels of CD26/DPPIV, and hematopoietically relevant cytokines.
Aim 2 : Evaluate how CD26/DPPIV mechanistically regulates hematopoiesis, using cell culture and biochemical studies on mouse and human cytokines and with cells from mouse BM and human CB. Hypothesis: CD26/DPPIV regulates hematopoiesis through: its specific enzymatic capability to truncate and inactivate different hematopoietically active cytokines. We will compare results to clinical study in Aim 1 to better understand and utilize this new treatment modality.
Sub aims i nclude: a) Evaluate how GM-CSF, G-CSF, IL-3 and EPO truncated by CD26/DPPIV, compared to full length form, signal intracellularly;b) Determine if systemic administration of sitagliptin to mice enhances homing of HSC and influences cytokine production;and c) Study other molecules for CD26/DPPIV truncation and activity.

Public Health Relevance

Cord blood transplantation is a viable treatment, but one disadvantage is the limiting number of cells in single cord blood collections, especially for adult recipients. By understanding how a cell surface enzyme, CD26, regulates blood cell production, and by specifically inhibiting this enzyme systemically in recipients of cord blood transplantation, we believe that donor cell engraftment will be greatly enhanced in adult recipients.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL112669-03
Application #
8670014
Study Section
Clinical Oncology Study Section (CONC)
Program Officer
Thomas, John
Project Start
2012-03-01
Project End
2017-02-28
Budget Start
2014-03-01
Budget End
2015-02-28
Support Year
3
Fiscal Year
2014
Total Cost
$1,394,744
Indirect Cost
$500,677
Name
Indiana University-Purdue University at Indianapolis
Department
Microbiology/Immun/Virology
Type
Schools of Medicine
DUNS #
603007902
City
Indianapolis
State
IN
Country
United States
Zip Code
46202
Broxmeyer, Hal E; Capitano, Maegan; Campbell, Timothy B et al. (2016) Modulation of Hematopoietic Chemokine Effects In Vitro and In Vivo by DPP-4/CD26. Stem Cells Dev 25:575-85
Messina-Graham, Steven; Broxmeyer, Hal (2016) SDF-1/CXCL12 modulates mitochondrial respiration of immature blood cells in a bi-phasic manner. Blood Cells Mol Dis 58:13-8
Lee, Man Ryul; Mantel, Charlie; Lee, Sang A et al. (2016) MiR-31/SDHA Axis Regulates Reprogramming Efficiency through Mitochondrial Metabolism. Stem Cell Reports 7:1-10
Huang, X; Lee, M-R; Cooper, S et al. (2016) Activation of OCT4 enhances ex vivo expansion of human cord blood hematopoietic stem and progenitor cells by regulating HOXB4 expression. Leukemia 30:144-53
Broxmeyer, Hal E (2016) Enhancing the efficacy of engraftment of cord blood for hematopoietic cell transplantation. Transfus Apher Sci 54:364-72
Xie, Jie; Broxmeyer, Hal E; Feng, Dongni et al. (2015) Human adipose-derived stem cells ameliorate cigarette smoke-induced murine myelosuppression via secretion of TSG-6. Stem Cells 33:468-78
Capitano, Maegan L; Chitteti, Brahmananda R; Cooper, Scott et al. (2015) Ames hypopituitary dwarf mice demonstrate imbalanced myelopoiesis between bone marrow and spleen. Blood Cells Mol Dis 55:15-20
Mantel, Charlie R; O'Leary, Heather A; Chitteti, Brahmananda R et al. (2015) Enhancing Hematopoietic Stem Cell Transplantation Efficacy by Mitigating Oxygen Shock. Cell 161:1553-65
Broxmeyer, Hal E; O'Leary, Heather A; Huang, Xinxin et al. (2015) The importance of hypoxia and extra physiologic oxygen shock/stress for collection and processing of stem and progenitor cells to understand true physiology/pathology of these cells ex vivo. Curr Opin Hematol 22:273-8
Capitano, Maegan L; Hangoc, Giao; Cooper, Scott et al. (2015) Mild Heat Treatment Primes Human CD34(+) Cord Blood Cells for Migration Toward SDF-1α and Enhances Engraftment in an NSG Mouse Model. Stem Cells 33:1975-84

Showing the most recent 10 out of 37 publications